Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:MDNA

Medicenna Therapeutics (MDNA) Stock Price, News & Analysis

Medicenna Therapeutics logo

About Medicenna Therapeutics Stock (NASDAQ:MDNA)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
$0.16
$0.39
52-Week Range
N/A
Volume
1.27 million shs
Average Volume
160,047 shs
Market Capitalization
$10.93 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$2.50
Consensus Rating
Buy

Company Overview

Medicenna Therapeutics Corp., an immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer and other diseases. It develops MDNA55, an interleukin- 4 (IL-4) EC for the treatment of recurrent glioblastoma, as well as for brain tumors. The company also develops MDNA11, an enhanced version of IL-2 to activate and proliferate the immune cells needed to fight cancer; MDNA209, an IL-2 antagonist for autoimmune diseases, such as multiple sclerosis and graft versus host disease; MDNA413, a dual IL-4/IL-13 antagonist to treat cancer immunotherapies; and MDNA132, an IL-13 Superkine for solid tumors. In addition, it provides BiSKITs platform to develop designer Superkines by fusing them to other proteins, antibodies, cytokines, or other Superkines. The company is headquartered in Toronto, Canada.

Receive MDNA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Medicenna Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

MDNA Stock News Headlines

“You all just got a lot richer”
Trump Knows What He’s Doing. When the president says he’s going to let RFK “go wild” … and Big Pharma crashes. Do you think that’s an accident? When he threatens to “End the Fed” do you think he doesn’t know banking stocks will benefit? What about when he tells his followers, “Now is a good time to buy,” hours before relaxing tariffs and sending the market soaring? Is that an accident? Larry Benedict doesn’t think so. He thinks Trump knows what he’s doing… and believes he’s found the perfect tickers for everyday Americans to take advantage next time he triggers a big move.
See More Headlines

MDNA Stock Analysis - Frequently Asked Questions

Medicenna Therapeutics Corp. (NASDAQ:MDNA) issued its earnings results on Friday, November, 12th. The company reported ($0.12) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.09) by $0.03.

Based on aggregate information from My MarketBeat watchlists, some other companies that Medicenna Therapeutics investors own include NVIDIA (NVDA), Broadcom (AVGO), CymaBay Therapeutics (CBAY), e.l.f. Beauty (ELF), Meta Platforms (META), Arista Networks (ANET) and AppLovin (APP).

Company Calendar

Last Earnings
11/12/2021
Today
5/28/2025
Fiscal Year End
3/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:MDNA
Employees
16
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$2.50
High Stock Price Target
$2.50
Low Stock Price Target
$2.50
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$7.60 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
$0.32 per share
Price / Book
N/A

Miscellaneous

Free Float
46,587,000
Market Cap
$10.93 million
Optionable
Not Optionable
Beta
1.30
(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

This page (NASDAQ:MDNA) was last updated on 5/28/2025 by MarketBeat.com Staff
From Our Partners